Delek US Holdings, Inc. (DK)
NYSE: DK · Real-Time Price · USD
20.77
-1.60 (-7.15%)
Aug 1, 2025, 4:00 PM - Market closed
Theseus Pharmaceuticals Stock Forecast
Stock Price Forecast
The 12 analysts that cover Theseus Pharmaceuticals stock have a consensus rating of "Hold" and an average price target of $20.6, which forecasts a -0.82% decrease in the stock price over the next year. The lowest target is $13.25 and the highest is $30.
Price Target: $20.60 (-0.82%)
Analyst Consensus: Hold
Analyst Ratings
The average analyst rating for Theseus Pharmaceuticals stock is "Hold". This means that analysts believe this stock is likely to perform similarly to the overall market.
Recommendation Trends
| Rating | Feb '25 | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Buy | 0 | 0 | 1 | 2 | 2 | 2 |
| Hold | 6 | 6 | 7 | 6 | 6 | 7 |
| Sell | 3 | 3 | 3 | 3 | 3 | 3 |
| Strong Sell | 1 | 1 | 1 | 1 | 1 | 1 |
| Total | 10 | 10 | 12 | 12 | 12 | 13 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Piper Sandler | Piper Sandler | Hold Maintains $17 → $27 | Hold | Maintains | $17 → $27 | +30.00% | Jul 22, 2025 |
| Citigroup | Citigroup | Hold Maintains $15 → $30 | Hold | Maintains | $15 → $30 | +44.44% | Jul 16, 2025 |
| Morgan Stanley | Morgan Stanley | Sell Maintains $15 → $19 | Sell | Maintains | $15 → $19 | -8.52% | Jul 16, 2025 |
| Raymond James | Raymond James | Buy Maintains $23 → $28 | Buy | Maintains | $23 → $28 | +34.81% | Jul 15, 2025 |
| Scotiabank | Scotiabank | Hold Maintains $14 → $20 | Hold | Maintains | $14 → $20 | -3.71% | Jul 11, 2025 |
Financial Forecast
Revenue This Year
10.98B
from 11.85B
Decreased by -7.40%
Revenue Next Year
10.70B
from 10.98B
Decreased by -2.51%
EPS This Year
-4.91
from -8.77
EPS Next Year
-2.23
from -4.91
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 12.8B | 12.7B | 11.7B |
| Avg | 11.0B | 10.7B | 10.7B |
| Low | 8.9B | 8.8B | 9.2B |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 8.1% | 15.4% | 9.1% |
| Avg | -7.4% | -2.5% | -0.1% |
| Low | -24.8% | -19.7% | -13.7% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -3.10 | 3.36 | 0.58 | ||
| Avg | -4.91 | -2.23 | -2.05 | ||
| Low | -5.40 | -4.21 | -5.15 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.